Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Brainomix

Explore full profile

Medical imaging company using artificial intelligence for the fast diagnosis and treatment of stroke victims

Oxford, United KingdomFounded 2010Biotech & Life Sciences
Valuation $100–250M Last recorded · 2025
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Brainomix and the history behind them.

About Brainomix

Brainomix is a healthcare technology company that specializes in developing AI-powered imaging solutions to improve stroke treatment. Founded in 2010 as a spin-out from the University of Oxford, Brainomix has grown to serve medical professionals globally, with its solutions being used in over 30 countries. The company focuses on creating imaging biomarkers—essentially, measurable indicators found in medical images—that help doctors make precise treatment decisions.

Read full description

Brainomix's flagship product, e-Stroke, is a comprehensive suite of tools designed to assist clinicians throughout the entire stroke treatment process. This includes diagnosing, triaging, and transferring patients to ensure they receive the right treatment at the right time. The e-Stroke suite includes several key components:

1. **e-ASPECTS**: This tool automatically assesses the severity of a stroke by analyzing CT images, detecting large vessel occlusions (LVOs) and hyperdense volumes that may indicate bleeding. It provides exact and reliable results every time, aiding in quick and accurate diagnosis.

2. **e-CTA**: This component standardizes the assessment of blood flow in the brain using CT angiography scans. It automatically detects LVOs and provides visual aids to help doctors understand the timing of blood flow.

3. **e-CTP**: This tool helps visualize blood flow and tissue viability, providing crucial information for treatment decisions.

Brainomix operates in the healthcare market, specifically focusing on stroke care. Its clients include hospitals, clinics, and medical professionals who need advanced tools to improve patient outcomes. The company makes money by selling its AI-powered software solutions to these healthcare providers, often through licensing agreements or subscription models.

In summary, Brainomix leverages cutting-edge AI technology to enhance the speed and accuracy of stroke diagnosis and treatment, ultimately aiming to save lives and improve patient outcomes.

**Keywords**: AI-powered, imaging solutions, stroke treatment, healthcare, biomarkers, diagnosis, triage, CT images, medical professionals, University of Oxford.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2010
Headquarters
Oxford, United Kingdom
Employees
86
Open positions
1
Dealroom signal
84.7/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Neurology
Technology
Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Computer Vision
Business model
SaaS
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Nov 2025 $6.3M $106M Undisclosed ↗
SERIES COther financing Mar 2025 $18M $106M Parkwalk Advisors · Hostplus · Boehringer Ingelheim Venture Fund ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Brainomix website traffic

Latest recorded traffic for Brainomix is 7.5K monthly website visits, down 9.6% over the last three months. Brainomix's team grew 6.2% over the past year.

Latest monthly visits7.5K 3-month web change-9.6% 1-year team growth+6.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Oxford University Innovation
  • European Innovation Council

Series A3 investors entered at this stage

  • Chimera Partners
  • Parkwalk Advisors
  • Tencent

Series B and later2 investors entered at this stage

  • Boehringer Ingelheim Venture Fund
  • Hostplus

Other known investors1 additional known investor

  • OUI Startup Incubator
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
11 countries with
team presence
🇬🇧 United Kingdom72.1%
🇺🇸 United States8.8%
🇨🇿 Czech Republic2.9%
🇪🇸 Spain2.9%
🇵🇱 Poland2.9%
Top 5 of 11 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Brainomix on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Brainomix’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.